Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Weak US Services Data Add To Market Gloom

Wed, 03rd Feb 2016 17:04

LONDON (Alliance News) - There was another afternoon sell-off for UK stock indices Wednesday, as Wall Street's opening gains swiftly turned to losses after two separate disappointing service purchasing managers' index readings.

The FTSE 100 closed down 1.4% at 5,837.14, marking its third successive session of losses. The FTSE 250 closed down 1.9% at 15,992.42, and the AIM All-Share ended down 0.5% at 690.27.

In Europe, the French CAC 40 closed down 1.3% and the German DAX 30 ended down 1.5%.

On Wall Street at the London close, the DJIA was down 0.2%, the S&P 500 down 0.6% and the Nasdaq Composite traded down 1.1%.

US stocks fell after a report from the Institute for Supply Management revealed growth in the US service sector slowed in January. The ISM said its non-manufacturing index dropped to 53.5 in January from an upwardly revised 55.8 in December, although a reading above 50 still indicates growth in the service sector. Economists had expected the index to inch up to 55.5 from the 55.3 originally reported for the previous month.

The decrease by the non-manufacturing index was partly due to a steep drop by the business activity index, which tumbled to 53.9 in January from 59.5 in December.

Anthony Nieves, chair of the ISM Non-Manufacturing Business Survey Committee, said "the majority of the respondents' comments are positive about business conditions; however, there is a concern that exists relative to global conditions, stock market volatility, and the effect on commercial and consumer confidence."

Separately Markit's services PMI for the US fell to 53.2 in January, its lowest reading since late 2013, against economists' expectations of a more modest fall to 53.7 from December's reading of 54.3.

Markit said its respondents were concerned that the wider economic outlook will constrain their growth opportunities in the coming year. Furthermore, respondents noted signs of a slowdown in cyclical demand, driven in part by greater caution about the economic outlook.

"Deteriorating financial market conditions, global growth uncertainties and the upcoming election are all taking their toll, not to mention the strong dollar, which is not only hurting manufacturing but is also hitting the service sector through reduced tourism and travel," said Chris Williamson, chief economist at Markit.

The dollar fell against other major currencies. At the European equity close, the euro traded the dollar at USD1.1052 versus USD1.0898 at the close Tuesday. The pound traded the dollar at USD1.4580, compared to the price close on Tuesday of USD1.4388.

The pound was also boosted by strong domestic services data. Survey figures from Markit Economics showed that the Chartered Institute of Procurement & Supply/Markit services PMI rose marginally to 55.6 in January from 55.5 in December against the consensus forecast of a fall to 55.4.

Markit said the UK's dominant service sector output has now been in expansion for over three years, with this year's figure slightly stronger than the long-run average but weaker than the growth seen in 2013, 2014 and 2015.

On the London Stock Exchange miners, so often the chains restricting the FTSE 100, made up the majority of the handful of gainers in the blue-chip index with Anglo American the best performer, up 8.6%, and both Glencore and Rio Tinto up 1.9%.

Also amongst the gainers was GlaxoSmithKline, up 0.8%, after the pharmaceutical giant posted results in line with expectations for 2015 and said it would hit its revenue target for new drugs ahead of schedule.

The company's closely-watched core earnings-per-share fell to 75.7 pence from the 95.4p it reported a year before, in line with the company's guidance and consensus expectations of 76.0p.

Glaxo reported a pretax profit of GBP10.53 billion, significantly up from the GBP2.97 billion it reported a year as a result of exceptional gains from a significant deal with Swiss peer Novartis in 2014, as it saw revenue of GBP23.92 billion, up from GBP23.00 billion a year before.

Elsewhere, Chief Executive Officer Andrew Witty echoed earlier sentiments that, following the company's deal with Novartis, there was now an option for "different structures" for the business in the future. The company has faced frequent speculation about a potential split-up in recent years, and this has heated up in the last few months after prominent fund manager Neil Woodford renewed calls for the company to be broken up.

The FTSE 350 Banking sector index closed down 3.6%, with banks ending amongst the heaviest fallers in the FTSE 100. Barclays closed down 4.7%, Standard Chartered down 4.3%, and HSBC Holdings down 3.7%, amongst others.

IG's senior market analyst Chris Beauchamp said: "A heady cocktail of worries – faltering economic growth, concerns about contagion from energy stocks and diminishing expectations regarding a Fed move have all conspired to send bank shares down around the world."

Adding to the concerns about the US Federal Reserve, New York Fed President William Dudley warned that the deteriorating outlook about the global growth and dollar strength would hurt the US economy. In an interview with MNSI, Dudley said the Fed would consider persistent tightening of financial conditions very seriously while pursuing its planned interest rate hikes.

Oil prices encountered volatility towards the end of the London equity trading session. Brent oil traded close to the USD33 a barrel marker for most of the day before dropping sharply on a report from the US Energy Information Administration saying its crude oil stocks rose by 7.8 million barrels in the week ending January 29, compared to the forecast for a 4.8 million barrel rise.

However, after a sharp drop Brent shot higher and at the London close was quoted at USD34.34 a barrel, compared to USD33.07 at Tuesday's close.

The gold price also rose as the dollar fell. At the London close it was quoted at USD1,138.90 an ounce versus USD1,125.76 on Tuesday.

In the economic calendar Thursday, European Central Bank President Mario Draghi will be making a speech in Frankfurt at 0800 GMT, just before the ECB releases its monthly economic bulletin at 0900 GMT. The Bank of England will then announce its policy decision, and simultaneously release its meeting minutes and inflation report at noon.

In the afternoon, US continuing and initial jobless claims are at 1330 GMT, as are unit labour cost data and nonfarm productivity. US factory orders are at 1500 GMT.

In the UK corporate calendar, oil and gas major Royal Dutch Shell, pharmaceutical company AstraZeneca, medical devices maker Smith & Nephew, specialist insurer Beazley and Primary Health Properties all report full-year results. There are also trading statements from Vodafone Group, caterer Compass Group and DFS Furniture, while easyJet releases January traffic statistics.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.